Pharmaceuticals, Biotechnology and Life Sciences
SBTI ID
40001422
Localisation
United States of America
Northern America
Secteur d'activité
Pharmaceuticals, Biotechnology and Life Sciences
Type d'organisation
Corporate
Dernière mise à jour
13/02/2025
Statut
Classification
1.5°C
Année cible
2033
Statut
Targets set
Classification
1.5°C
Année cible
2050
Overall Net-Zero Target: Genscript Biotech Corporation commits to reach net-zero greenhouse gas emissions across the value chain by 2050. Near-Term Targets: Genscript Biotech Corporation commits to reduce absolute scope 1 and 2 GHG emissions 54.6% by 2033 from a 2023 base year. Genscript Biotech Corporation also commits to reduce absolute scope 3 GHG emissions from fuel and energy related activities and waste generated in operations 32.5% within the same timeframe. Genscript Biotech Corporation finally commits that 83% of its suppliers by emissions covering purchased goods and services, capital goods, and upstream transportation and distribution, will have science-based targets by 2029. Long-Term Targets: Genscript Biotech Corporation commits to reduce absolute scope 1 and 2 GHG emissions 90% by 2050 from a 2023 base year. Genscript Biotech Corporation also commits to reduce absolute scope 3 GHG emissions 90% within the same timeframe.
Statut
Targets setAnnée cible
2050
The targets covering greenhouse gas emissions from company operations (scopes 1 and 2) are consistent with reductions required to keep warming to 1.5°C
ISIN
KYG3825B1059
LEI
529900YIYUOJOXSAE372
Source : Science Based Targets initiative | Données publiques